Allergy

Patients with allergic rhinitis report less satisfaction with oral antihistamines than intranasal corticosteroids or combination therapies.

A recent study reveals that small intestinal dilation significantly contributes to abdominal symptoms in adults with Food-Protein-Induced Enterocolitis Syndrome (FPIES).

A new trial reveals that educational interventions significantly enhance pediatricians' adherence to guidelines for early peanut introduction.

Subcutaneous Dpg-pol-cat significantly improved the quality of life and reduced medication use in adults with moderate to severe cat allergy.

Donidalorsen demonstrates strong efficacy in patients switching from other HAE prophylactic treatments. Lumry discusses pivotal data after FDA approval.

Lumry discuses donidalorsen, the first FDA-approved, RNA-targeted therapy for hereditary angioedema.

An audio recap of the top 5 stories in healthcare news from the week of 9/28-10/04.

Explore the latest advancements in allergy and immunology, including new therapies, FDA approvals, and innovative clinical strategies for improved patient care from Q3.

Explore key FDA decisions in Q4 2025, impacting treatments for atopic dermatitis, chronic rhinosinusitis, and rare diseases.

This month in review features the latest breakthroughs in allergy treatments, including innovative therapies for cat and peanut allergies.

A study found 3% hypertonic saline nasal irrigation reduced symptoms in allergic rhinitis but offered no significant advantage over isotonic saline.

A meta-analysis confirmed CARATkids as a reliable tool for assessing asthma and allergic rhinitis control in children aged 6–12 years.

The MACRO study provided no support for long-term clarithromycin use in patients with chronic rhinosinusitis, only supporting endoscopic sinus surgery.

Avapritinib shows significant long-term benefits for indolent systemic mastocytosis while maintaining a favorable safety profile.

A study shows children in remission can safely consume peanuts without daily dosing, supporting remission as the primary treatment goal over desensitization.

An audio recap of the top 5 stories in healthcare news from the week of 9/5-9/13.

Real-world data show epinephrine nasal spray achieved an 89.2% success rate in treating anaphylaxis, nearly identical to the injection’s response rate.

Stay updated with the latest healthcare breakthroughs, including FDA news and the voluntary withdrawal of obeticholic acid, in this week's essential news roundup.

Akin discussed updated data on elenestinib from the HARBOR trial in indolent systemic mastocytosis.

In over 500 patients, a single dose of neffy achieved an 89% success rate, matching injection outcomes and supporting its use as a needle-free alternative.

Regeneron's innovative antibody therapies show promising results in alleviating cat and birch allergies.

A study shows that sex modifies HRQL outcomes in peanut OIT: males benefit most from active treatment, while females show strong placebo gains.

Cluster protocol VIT demonstrates high efficacy in children with venom allergies, showing low systemic reactions and strong protection against re-stings.

Upstream Bio’s VIBRANT trial finds verekitug, a monoclonal antibody binding to the TSLP receptor, reduces nasal polyps in patients with CRSwNP.

This month in review features the top 5 allergy news in August 2025, including FDA approvals, updated guidelines, and emerging research.